### RECEIVED **CENTRAL FAX CENTER**

11-28-06; 5:03PM;SSMP FAX

NOV 2 8 2006

;5167424366

BEST AVAILABLE COPY TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) 17406 In Re Application Of: Akio Uchiyama Application No. Customer No. **Group Art Unit** Confirmation No. Filing Date Examiner 10/766,581 23389 3837 January 27, 2004 Matthew J. Kasztejna 3739 CAPSULE MEDICAL DEVICE Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p).

# NOV 2 8 2006 BEST AVAILABLE COPY

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 17406					
In Re Application O	f: Akio Uchiyama									
Application No.	oplication No. Filing Date Examiner Cus		Customer No.	Group Art Unit	Confirmation No.					
10/766,581	1 January 27, 2004 Matthew J. Kasztejna 23389		3739	3837						
Title: CAPSULE	MEDICAL DEVICE									
Address to:  Commissioner for Paterits  P.O. Box 1450  Alexandria, VA 22313-1450										
		37 CFR 1.97(b)								
1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.										
		37 CFR 1.97(c)								
2. A The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:										
☐ the statement specified in 37 CFR 1.97(e);										
	•	OR								
🖾 the f	the fee set forth in 37 CFR 1.17(p).									
	-									

NOV 2 8 2006 B						ILABLE CO				
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))						Docket No. 17406				
In Re Application o	f: Akio Uchiyama									
Application No.	Filing Date	Examiner		Customer No.	Group Art Unit	Confirmation No.				
10/766,581	January 27, 2004	Matthew J. Kas	ztejna	23389	3739	3837				
Title: CAPSULE	MEDICAL DEVICE									
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))										
□ A check in the amount of is attached. □ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. □ Charge the amount of \$180.00 □ Credit any overpayment. □ Charge any additional fee required. □ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.  Certificate of Transmission by Facsimile* □ Certificate of Mailing by First Class Mail □ Certify that this document and authorization to charge deposited account is being facsimile transmitted to the United States Patent and Trademark Office (Fa  November 28, 2006 □ (Date) □ (Date) □ (Date) □ (Pate) □ (Pate) □ (Pate) □ (Pate) □ (Pate) □ (Pate)										
Seth Weinfel	Nufly Significant		Signature of Person Mailing Correspondence							
il	ringed Name of Person Sign	ing Certificate	Туре	ed or Printed Name (	of Person Mailing Ce	rtificate				
deposit accou	Signature J	Daying by	Dated: I	November 28, 20	<b>006</b>					
Seth Weinfeld, Reg. Scully, Scott, Murph										
cc:										

### RECEIVED CENTRAL FAX CENTER

NOV 2 8 2006

## **BEST AVAILABLE COPY**

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Akio Uchiyama

Examiner:

Kasztejna, Matthew J.

Serial No:

10/766,581

Art Unit:

3739

Filed:

January 27, 2004

Docket:

17406

For:

CAPSULE MEDICAL

Dated:

November 28, 2006

**DEVICE** 

Confirmation No. 3837

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### **INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following reference, which is also listed on the attached Form PTO-1449, be made of record in the above-identified case.

- 1. U. S. Patent 5,604,531 dated February 18, 1997 issued to Iddan et al.
- 2. U. S. Patent 6,951,536 dated October 4, 2005 to Yokoi et al.

#### **CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to (571)-273-8300 at the Patent and Trademark Office on the date shown below.

Dated: November 28, 2006

Seth Weinfeld

11/29/2006 HVUONG1 00000007 191013

10766581

01 FC:1806

180.00 DA

## **BEST AVAILABLE COPY**

- 3. U. S. Patent 7,061,523 dated June 13, 2006 to Fujita et al.
- 4. U. S. Patent 7,076,284 dated July 11, 2006 to Segawa et al.

In accordance with 37 C.F.R. 1.98 (a)(2)(i) and (ii) the above cited references are not enclosed.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(c), please charge deposit account 19-1013 SSMP the \$180.00 fee.

Respectfully submitted;

Seth Weinfold

Registration No: 50,929

Scully, Scott, Murphy & Presser, P.C. 400 Garden City Plaza, Suite 300 Garden City, New York 11530 516-742-4343

SW:ae

# BEST AVAILABLE COPY Sheet 1 of 1

10/766,581									
Applicant(s) Akio Uchiyama									
Group Art Unit									
3739									
U.S. PATENT DOCUMENTS									
	DATE opriate)								
TRANSLATION									
YES	NO								
	:								
	-								
ges, Etc.)									
EXAMINER DATE CONSIDERED									
n conforms	nce and								
	TRANSI YES								